IL-3z.CAR CAR-CIK cells

IL-3z.CAR CAR-CIK cells are an experimental adoptive cell therapy consisting of cytokine-induced killer (CIK) cells engineered to co-express a dual-receptor system for the treatment of acute myeloid leukemia (AML). The construct features a first-generation, low-affinity anti-CD123 interleukin-3–zetakine (IL-3z) chimeric antigen receptor (CAR) and an anti-CD33 costimulatory receptor (CCR) that lacks primary activation signaling domains. This trans-signaling strategy is designed to enhance tumor selectivity by requiring the simultaneous engagement of both CD123 and CD33 antigens for full CIK cell activation. By utilizing a low-affinity IL-3z CAR, the therapy aims to minimize 'on-target/off-tumor' toxicity against healthy endothelial cells (which express CD123) and hematopoietic stem/progenitor cells (which express CD33), while maintaining potent anti-leukemic activity against double-positive AML blasts. The therapy was developed by researchers at the University of Milano-Bicocca and the University of Perugia.

Other names

IL-3z.CAR CAR-CIKIL3z.CAR CAR-CIKIL 3z.CAR CAR-CIKCD123/CD33 dual-targeting CAR-CIK cellslow affinity dual targeting IL-3z.CAR/CD33.CCR CIK cellsIL-3 zetakine CAR-CIK cellsIL3 zetakine CAR-CIK cellsIL 3 zetakine CAR-CIK cells